Apogee Therapeutics Reports $74.1 Million Net Loss and Significant Cash Increase for Q1 2026

Apogee Therapeutics, Inc. reported a net loss of $74.1 million for the three months ended March 31, 2026, compared to a net loss of $55.3 million for the same period in 2025. The company's total operating expenses increased to $82.8 million from $63.1 million year-over-year, driven primarily by higher research and development costs, which rose to $60.8 million from $46.4 million. General and administrative expenses also saw an increase, totaling $22.0 million compared to $16.7 million in the prior year. The increase in expenses reflects ongoing investments in clinical trials and the expansion of the company's workforce.

In terms of financial position, Apogee's cash and cash equivalents surged to $451.8 million as of March 31, 2026, up from $131.5 million at the end of 2025. The company also reported marketable securities of $608.1 million, contributing to total assets of $1.3 billion, a significant increase from $937.1 million at the end of the previous fiscal year. This growth in liquidity is attributed to successful equity offerings, including a recent public offering that generated net proceeds of $377.4 million.

Operationally, Apogee is advancing its clinical pipeline, which includes several antibody programs targeting inflammatory and immunology conditions. The company has initiated multiple clinical trials, including the APEX Phase 2 trial for its lead candidate, zumilokibart (APG777), which is being evaluated for the treatment of atopic dermatitis. The company reported positive interim results from this trial, indicating a strong efficacy profile and a favorable safety profile. Apogee is also exploring combination therapies with other candidates in its pipeline, such as APG279 and APG273, which combine zumilokibart with other monoclonal antibodies.

Looking ahead, Apogee anticipates continued investment in research and development, with plans to initiate Phase 3 trials for zumilokibart in the second half of 2026, pending positive results from ongoing studies. The company expects that its existing cash and marketable securities will be sufficient to fund operations through at least the next 12 months, supporting its strategic objectives in advancing its clinical programs and potential commercialization efforts. However, the company acknowledges the inherent risks and uncertainties associated with drug development and the need for additional funding to support its long-term growth strategy.